

CITATION REPORT

List of articles citing

Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma

DOI: 10.1002/lt.25202

Liver Transplantation, 2018, 24, 1171-1177.

Source: <https://exaly.com/paper-pdf/71060056/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
40	Hepatocellular carcinoma: Where are we in 2018?. <i>Current Problems in Surgery</i> , 2018 , 55, 450-503	2.8	1
39	Harms of hepatocellular carcinoma surveillance. <i>Current Hepatology Reports</i> , 2019 , 18, 383-389	1	3
38	Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919869120	5.4	36
37	Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. <i>Journal of Hepatocellular Carcinoma</i> , 2019 , 6, 23-30	5.3	9
36	The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	23
35	Epidemiological and etiological variations in hepatocellular carcinoma. <i>Infection</i> , 2020 , 48, 7-17	5.8	64
34	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	1
33	Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 3456-3462	4	7
32	Identifying High-Risk NASH Patients: What We Know so Far. <i>Hepatic Medicine: Evidence and Research</i> , 2020 , 12, 125-138	3.4	11
31	Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. <i>Cancers</i> , 2020 , 12,	6.6	16
30	NAFLD-related HCC. <i>Advances in Cancer Research</i> , 2021 , 149, 143-169	5.9	2
29	Non-enhanced Magnetic Resonance Imaging Compared to Ultrasound as a Surveillance Tool for Hepatocellular Carcinoma. Not all that glitters is gold: the ultrasound hepatologist's point of view. <i>Journal of Ultrasound</i> , 2021 , 1	3.4	
28	Performance of Ultrasound Techniques and the Potential of Artificial Intelligence in the Evaluation of Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease. <i>Cancers</i> , 2021 , 13,	6.6	3
27	Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
26	Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	10
25	Inadequate Ultrasound Examination in Hepatocellular Carcinoma Surveillance: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	
24	Abbreviated MR Protocols for Chronic Liver Disease and Liver Cancer. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2021 , 29, 321-327	1.6	0

23	Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	10
22	Analytical validation of a novel multi-target blood-based test to detect hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2021 , 21, 1245-1252	3.8	2
21	NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. <i>Journal of Hepatology</i> , 2021 ,	13.4	12
20	Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma. <i>Transplantation Direct</i> , 2020 , 6, e605	2.3	1
19	HCC screening: assessment of an abbreviated non-contrast MRI protocol. <i>European Radiology Experimental</i> , 2019 , 3, 49	4.5	20
18	Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI. <i>Hepatoma Research</i> , 2020 , 6,	4.3	6
17	Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography. <i>Cancers</i> , 2020 , 12,	6.6	6
16	A Computed Tomography Nomogram for Assessing the Malignancy Risk of Focal Liver Lesions in Patients With Cirrhosis: A Preliminary Study.. <i>Frontiers in Oncology</i> , 2021 , 11, 681489	5.3	
15	Conventional and novel biomarkers for the diagnosis and prognosis of liver cancer. 2022 , 281-306		
14	Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022	6.1	3
13	Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.. <i>The Cochrane Library</i> , 2022 , 5, CD014798	5.2	1
12	The unmet need of personalized HCC screening-Lessons learned from the Swedish nationwide registries.. <i>United European Gastroenterology Journal</i> , 2022 ,	5.3	
11	Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. <i>Journal of Hepatocellular Carcinoma</i> , Volume 9, 477-496	5.3	1
10	Abbreviated Liver Magnetic Resonance Imaging Protocols and Applications. <i>Radiologic Clinics of North America</i> , 2022 ,	2.3	
9	New horizon of ultrasound for screening and surveillance of non-alcoholic fatty liver disease spectrum. <i>European Journal of Radiology</i> , 2022 , 110450	4.7	
8	Current Imaging Diagnosis of Hepatocellular Carcinoma. 2022 , 14, 3997		2
7	Impact of ultrasonographic blind spots for early-stage hepatocellular carcinoma during surveillance. 2022 , 17, e0274747		0
6	HCC Surveillance in Patients with NAFLD.		0

- 5 Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?. **2022**, 2
- 4 HCC screening with ultrasound: assessment of quality using ultrasound LI-RADS score. 0
- 3 Clinical features and management issues of NAFLD-related HCC: what we know so far. **2023**, 17, 31-43 0
- 2 Improving artificial intelligence pipeline for liver malignancy diagnosis using ultrasound images and video frames. **2023**, 24, 0
- 1 Non-alcoholic fatty liver disease-related hepatocellular carcinoma. **2023**, 23, 127-142 0